Selinexor: all 154 studies that test it

Page 1 of 2. Open to participants first (46), then studies with results posted, then the rest; newest registration first within each.

• Imlunestrant/Abemaciclib/Selinexor in Ovarian and EndometrialNot yet recruitingNCT07832227Phase 2
• The Efficacy and Safety of Selinisole Combined With Azacitidine and Venetoclax in the Treatment of Newly Diagnosed High-risk Myeloid Tumors With TP53 MutationsNot yet recruitingNCT07632170Not applicable
• Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative NeoplasmsNot yet recruitingNCT07626021Phase 2
• A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell LymphomaNot yet recruitingNCT07574528Phase 2
• Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell LymphomaNot yet recruitingNCT07554482Phase 2
• Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple MyelomaRecruitingNCT07479979Phase 1/2
• Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With CytopeniasNot yet recruitingNCT07447817Phase 2
• Golidocitinib Combined With Selinexor for CAEBVDRecruitingNCT07369739Phase 2/3
• Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell LymphomaNot yet recruitingNCT07276698Phase 2
• Selinexor Maintenance Post CAR-T Cell Therapy for Multiple MyelomaRecruitingNCT07200102Phase 1
• A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA）RecruitingNCT07191431Not applicable
• Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung CancerNot yet recruitingNCT07172412Phase 2
• A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07138209Phase 3
• A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCLRecruitingNCT06966154Phase 1/2
• Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms PatientsNot yet recruitingNCT06900088Phase 2
• Second-line Immunotherapy for ES-SCLCRecruitingNCT06853678Not applicable
• HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMMRecruitingNCT06822972Phase 2
• Using Tumor Models to Determine TreatmentsRecruitingNCT06813079Phase 2
• Twice-per-weekSelinexor, 2 Days MelphalanNot yet recruitingNCT06613035Phase 3
• "Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCLRecruitingNCT06559553Phase 1/2
• A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System LymphomaRecruitingNCT06556199Phase 1/2
• Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin LymphomaRecruitingNCT06552559Phase 1/2
• NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)RecruitingNCT06239272Phase 1/2
• A Trial of Selinexor, Ruxolitinib and MethylprednisoloneRecruitingNCT06225310Phase 1
• Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)RecruitingNCT06114004Phase 2
• A Study of Selinexor in People With Wilms Tumors and Other Solid TumorsRecruitingNCT05985161Phase 2
• Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian CancerRecruitingNCT05983276Phase 2
• A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaRecruitingNCT05980806Phase 2
• An Open, Single Center, Non-randomized, Single Arm Clinical Study of Evaluating the Efficacy of Selinexor in the Maintenance Treatment of PTCLRecruitingNCT05822050Phase 2/3
• Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) PatientsNot yet recruitingNCT05805072Not applicable
• Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD ResultsRecruitingNCT05736978Phase 2
• A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid LeukemiaRecruitingNCT05736965Phase 2
• Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT05726110Phase 3
• Selinexor in Combination With MTX+Ritu to Treat R/R CNSLRecruitingNCT05698147Phase 1/2
• Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple MyelomaRecruitingNCT05597345Phase 2
• Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL PatientsRecruitingNCT05577364Phase 1/2
• Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple MyelomaRecruitingNCT05530421Phase 2
• Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous TreatmentRecruitingNCT05432804Phase 1/2
• Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell LymphomaRecruitingNCT05422066Phase 2
• Selinexor Plus VRd in High Risk Newly Diagnosed Multiple MyelomaRecruitingNCT05422027Phase 1/2
• Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM TrialRecruitingNCT05333458Phase 2
• Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)RecruitingNCT05035745Phase 1/2
• ATG-010(Selinexor) in Combination With Chemotherapy in RRMMRecruitingNCT04877275Phase 2
• A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple MyelomaRecruitingNCT04661137Phase 2
• Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and OsteosarcomaRecruitingNCT04595994Phase 1
• Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.RecruitingNCT04519476Phase 1
• Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT04925193Phase 2Results posted
• Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial CarcinomaTerminatedNCT04856189Phase 1/2Results posted
• A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS MutationsTerminatedNCT04854434Phase 2Results posted
• Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma PatientsTerminatedNCT04843579Phase 2Results posted
• Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced MelanomaTerminatedNCT04768881Phase 2Results posted
• Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple MyelomaActive, not recruitingNCT04756401Phase 2Results posted
• A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent GlioblastomaTerminatedNCT04421378Phase 1/2Results posted
• Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 InfectionCompletedNCT04349098Phase 2Results posted
• Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination TreatmentCompletedNCT04256707Phase 1/2Results posted
• Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed GlioblastomaActive, not recruitingNCT04216329Phase 1Results posted
• A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT03992339Phase 2Results posted
• A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple MyelomaCompletedNCT03944057Phase 2Results posted
• Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 InhibitorsTerminatedNCT03627403Phase 2Results posted
• Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary ChemotherapyTerminatedNCT03193437Phase 2Results posted
• Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple MyelomaCompletedNCT03110562Phase 3Results posted
• Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)TerminatedNCT03095612Phase 1/2Results posted
• Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid LeukemiaTerminatedNCT03071276Phase 2Results posted
• Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple MyelomaCompletedNCT02780609Phase 1/2Results posted
• Selinexor in Advanced LiposarcomaCompletedNCT02606461Phase 2/3Results posted
• Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid LeukemiaCompletedNCT02530476Phase 1/2Results posted
• Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02416908Phase 1/2Results posted
• Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)CompletedNCT02402764Phase 2Results posted
• Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal CancerTerminatedNCT02384850Phase 1Results posted
• Selinexor in Treating Patients With Relapsed Small Cell Lung CancerTerminatedNCT02351505Phase 2Results posted
• Selinexor Treatment of Refractory MyelomaCompletedNCT02336815Phase 2Results posted
• Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade GliomasCompletedNCT02323880Phase 1Results posted
• Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell LymphomaTerminatedNCT02314247Phase 2Results posted
• Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin LymphomaCompletedNCT02303392Phase 1Results posted
• A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)CompletedNCT02249091Phase 2Results posted
• Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic SyndromesCompletedNCT02228525Phase 2Results posted
• Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate CancerTerminatedNCT02215161Phase 2Results posted
• Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell CarcinomasTerminatedNCT02213133Phase 2Results posted
• Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple MyelomaCompletedNCT02186834Phase 1/2Results posted
• SHIP (Selinexor in Hormone Insensitive Prostate Cancer)TerminatedNCT02146833Phase 2Results posted
• Selinexor in Initial or Refractory and/or Relapsed Richter's TransformationTerminatedNCT02138786Phase 2Results posted
• Selinexor (KPT-330) in Older Patients With Relapsed AMLCompletedNCT02088541Phase 2Results posted
• Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic MalignanciesCompletedNCT02025985Phase 2Results posted
• Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent GliomasTerminatedNCT01986348Phase 2Results posted
• A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With SarcomaCompletedNCT01896505Phase 1Results posted
• Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological CancerCompletedNCT01607892Phase 1Results posted
• A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCTActive, not recruitingNCT07779031Phase 1/2
• Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AMLActive, not recruitingNCT07437170Phase 2
• Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCHActive, not recruitingNCT07204041Phase 2
• Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After TransplantationActive, not recruitingNCT07094464Phase 1
• Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense ChemotherapyTerminatedNCT06449482Phase 1/2
• Selinexor, Cyclophosphamide and Prednisone in MyelomaCompletedNCT06212596Phase 2
• Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple MyelomaActive, not recruitingNCT06169215Phase 2
• Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06158841Phase 3
• Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid TumorsWithdrawnNCT05952687Phase 1
• Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) PatientsStatus unknownNCT05951855Phase 2
• SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary DiseaseCompletedNCT05900882Phase 2
• Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell LymphomaStatus unknownNCT05786989Phase 4
• Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaActive, not recruitingNCT05611931Phase 3
• A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaTerminatedNCT05354362Phase 1

← Selinexor overview